Arcutis Biotherapeutics Inc (ARQT) News

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while...

Form 4 - Statement of changes in beneficial ownership of securities

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

ARQ-255 is a topical Janus kinase 1 (JAK1) inhibitor suspension formulated as a potential topical treatment for...

Form 144 - Report of proposed sale of securities

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Long-term safety and tolerability profile consistent with pivotal data in atopic dermatitis (AD), with no new...

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a...

Cisco Beats Estimates and Announces Restructuring, Canoo Rises 6%, Lulus Losses Widen, Latest in Earnings

Cisco Systems (NASDAQ:CSCO) – The networking and IT solutions company reported adjusted earnings of 87...

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream...

U.S. Futures Steady After Tuesday’s Strong Recovery; CPI in Focus

U.S. stock index futures are little changed in pre-market trading on Wednesday after a strong recovery in...

Form 4 - Statement of changes in beneficial ownership of securities